BUSINESS CASE

Case Study Analysis: Transparency Policy 0070



CHALLENGE





A leading global pharmaceutical company, interested in full regulatory support for the management of Policy 0070 for a new active substance on the centralized procedure registration

The Client faced the following challenges:

- **Lack of experience** and technical know-how (first time dealing with Policy 0070).
- Not having in-house resources.
- Large documentation package (more than 60,000 pages).
- Tight timeframe.

The activities performed by Asphalion included:

- Specialised regulatory support.
- List of Expected Documents revision and determination of out of scope pages.
- Establishment of Risk Assessment approach.
- Pre-submission meeting preparation and attendance to define the anonymisation strategy.
- Definition of detailed **anonymisation rules** and **anonymisation report** preparation.
- Compilation of justification tables for commercially confidential Information, including guidance in formulating strong and substantiated explanations.
- **Execution of anonymisation** and redaction processes, including Quality Check.
- Publishing and submission activities.
- Liaison with the EMA Clinical Data Publication team.

Successful Policy 0070 implementation:

- Successful pre-submission meeting, agreeing with the EMA on the anonymisation strategy and achieving an extension of timelines.
- First time validation of Redaction Proposal Document Package.
- Acceptance of written responses to the Agency's observations without additional comments.
- Adaptation to the change of the Anonymisation Report Form template.
- Delivery of Final Redacted Document Package with minor comments.
- Completion of the project within the agreed timelines and competitive budget.



CLIENT TESTIMONIAL

"Many thanks for your **expertise** and patience to walk us through the EMA policy exercise and for the **successful approach** to comply with the EMA's CCI and PPD rules".

